A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP)

被引：0
|
作者：
Al-Batran, S.
Hartmann, J. T.
Probst, S.
Hofheinz, R.
Stoehlmacher, J.
Schmalenberg, H.
Hollerbach, S.
Schuch, G.
Homann, N.
Jaeger, E.
机构：
[1] Krankenhaus NW Frankfurt, Frankfurt, Germany
[2] Univ Tubingen, Tubingen, Germany
[3] Stadt Kliniken, Bielefeld, Germany
[4] Univ Klinikum Mannheim, Mannheim, Germany
[5] Univ Hosp Carl Gustav Carus, Dresden, Germany
[6] Univ Klinikum Jena, Jena, Germany
[7] Allgemeines Krankenhaus, Celle, Germany
[8] Univ Hamburg, Hosp Eppendorf, D-20246 Hamburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：934S / 934S
页数：1
相关论文
共 50 条
  • [1] Final results of a randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLIP)
    Al-Batran, S. E.
    Hartmann, J. T.
    Probst, S.
    Hofheinz, R.
    Stoehlmacher, J.
    Pauligk, C.
    Hollerbach, S.
    Schuch, G.
    Homann, N.
    Jaeger, E.
    EJC SUPPLEMENTS, 2007, 5 (04): : 259 - 260
  • [2] Fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP) as a first line therapy in patients with advanced gastric cancer-interim analysis of a multicenter, randomized phase II trial
    Schuch, G.
    Al-Batran, S.
    Derigs, H. G.
    Hartmann, J. T.
    Probst, S.
    Hegewisch-Becker, S.
    Stoehlmacher, J.
    Schmalenberg, S.
    Bokemeyer, C.
    Jaeger, E.
    EJC SUPPLEMENTS, 2005, 3 (02): : 211 - 212
  • [3] Fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP) as a first line therapy for patients with advanced gastric cancer;: first interim analysis of a randomised multicenter phase II study
    Al-Batran, SE
    Stöhlmacher, J
    Probst, S
    Hollerbach, S
    Wilhelm, G
    Derigs, HG
    Seipelt, G
    Kojouharoff, G
    Graubner, M
    Hinke, A
    Jäger, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 311S - 311S
  • [4] Biweekly oxaliplatin, fluorouracil and leucovorin versus cisplatin, fluorouracil and leucovorin in patients with advanced gastric cancer
    Popov, I.
    Radosevic-Jelic, L.
    Jezdic, S.
    Milovic, M.
    Borojevic, N.
    Stojanovic, S.
    Stankovic, V.
    Josifovski, T.
    Kezic, I.
    JOURNAL OF BUON, 2008, 13 (04): : 505 - 511
  • [5] FOLFOX (oxaliplatin and leucovorin plus fluorouracil) versus FOLFIRI (irinotecan and leucovorin plus fluorouracil) chemotherapy as a first-line treatment in a patients with unresectable metastatic or recurred gastric adenocarcinoma
    Tak, Dae Hyun
    Kim, Seok Hyun
    Moon, Hee Seok
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 : 261 - 261
  • [6] Impact of first-line fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with advanced gastroesophageal adenocarcinoma: A retrospective analysis
    Lino, Aline Da Rocha
    Moreira, Raphael Brandao
    Gomes, Jessica Ribeiro
    Soares de Sousa, Tarcia Tarciane
    Abrahao, Carina Mina
    Martins Junior, Rodnei Merlrina
    Alessandretti, Matheus Bongers
    Fernandes Amarante, Marcus Paulo
    Barros Schutz, Fabio Augusto
    Kawamura, Carolina
    Schmerling, Rafael
    Cruz, Marcelo Rocha
    Maluf, Fernando C.
    Buzaid, Antonio C.
    Peixoto, Renata D'Alpino
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [7] Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
    de Gramont, A.
    Figer, A.
    Seymour, M.
    Homerin, M.
    Hmissi, A.
    Cassidy, J.
    Boni, C.
    Cortes-Funes, H.
    Cervantes, A.
    Freyer, G.
    Papamichael, D.
    Le Bail, N.
    Louvet, C.
    Hendler, D.
    de Braud, F.
    Wilson, C.
    Morvan, F.
    Bonetti, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (33) : 5080 - 5089
  • [8] RANDOMIZED COMPARISON OF FLUOROURACIL AND LEUCOVORIN THERAPY VERSUS FLUOROURACIL, LEUCOVORIN, AND CISPLATIN THERAPY IN PATIENTS WITH ADVANCED COLORECTAL-CANCER
    SCHEITHAUER, W
    DEPISCH, D
    KORNEK, G
    PIDLICH, J
    ROSEN, H
    KARALL, M
    PROCHASKA, M
    ERNST, A
    SEBESTA, C
    ECKHARDT, S
    CANCER, 1994, 73 (06) : 1562 - 1568
  • [9] Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
    de Gramont, A
    Figer, A
    Seymour, M
    Homerin, M
    Hmissi, A
    Cassidy, J
    Boni, C
    Cortes-Funes, H
    Cervantes, A
    Freyer, G
    Papamichael, D
    Le Bail, N
    Louvet, C
    Hendler, D
    de Braud, F
    Wilson, C
    Morvan, F
    Bonetti, A
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) : 2938 - 2947
  • [10] Oxaliplatin,Fluorouracil and Leucovorin (FOLFOX) as First-line Chemotherapy for Metastatic or Recurrent Colorectal Cancer Patients
    Bing Han Ruihua Xu Yanxia Shi Huiyan Luo Xiaojuan Xiang Yuhong Li Li Zhang Tongyu Lin Youjian HeDepartment of Medical Oncology
    Chinese Journal of Clinical Oncology, 2007, (06) : 397 - 400
12345